In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Ines Lains, MD, PhD, detailed how adjunct treatment with intravitreal antivirals or early pars plana vitrectomy did not improve the rates of retinal detachment in patients diagnosed with acute retinal necrosis.
During a presentation at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, Ines Lains, MD, PhD, and colleagues from the Massachusetts Eye and Ear, Harvard Medical School, Boston, outlined how adjunct treatment with intravitreal antivirals or early pars plana vitrectomy (PPV) did not improve the rates of retinal detachment (RD) in patients diagnosed with acute retinal necrosis (ARN).
ARN is rare but can have devastating visual consequences, Lains explained. Over time, patients with ARN have a high risk of developing retinal traction and necrotic retinal breaks, which can lead to the development of a RD.
“RD is one of the most common consequences of ARN,” she said.
Systemic antivirals are the mainstay treatment for ARN, and even though clinicians may empirically add intravitreal antivirals or early PPV, data on this topic remains controversial.
The investigators conducted a cross-sectional retrospective cohort study using IRIS Registry data to determine the association between the initial treatment regimen for ARN and RD rates at 6 and 12 months.
The researchers identified 533 eyes of 457 patients that met their criteria. Among them, 358 cases (67.2%) received only systemic antivirals, while 155 (29.1%) received adjunctive intravitreal antivirals, and 20 (3.8%) underwent early PPV.
Results of analysis of ARN data
“At 6 months, the rates of RD were comparable among eyes treated with systemic antivirals alone (19.6%), adjunctive intravitreal antivirals (18.7%, p = 0.80) and early PPV (25.0%, p = 0.51),” they reported. Similar results also were seen at the 12-month evaluation (p > 0.47).
The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early PPV did not affect the time to development of RDs (p > 0.47).